17 / 23
Page 56
Notes:
allied
academies
Journal of Medical Oncology and Therapeutics | Volume: 3
July 23-25, 2018 | Moscow, Russia
12
th
World Cancer Congress
Pharmacoeconomic evaluation of regorafenib asmetastatic Colorectal Cancer treatment within Russian
healthcare context
Alexey Cheberda
Center for Pharmacoeconomics Research, Russia
B
y prevalence, colorectal cancer occupies third place
among the malignant oncological conditions in men,
and second in women. Regorafenib presents significant
clinical interests due to having demonstrated efficacy
in both patients with wild-type and mutant-type KRAS
gene, especially in patients demonstrating progression
despite chemotherapy, use of anti-VEGF and anti-EGFR
treatments. This pharmacoeconomic research was carried
out to evaluate use of regorafenib in wild-type KRAS patients
with metastic colorectal cancer patients who have shown
progression on anti-VEGF or had counter-indications to
anti-VEGF therapy and who have not received but could
receive anti-EGFR treatment. A model was constructed to
carry out budget impact analysis of regorafenib compared
to cetuximab and panitumumab. Sensitivity analysis and
lost opportunity analysis were also performed. Treatment
length was accounted for, and relevant randomized clinical
trials were used as sources of data in this regards. It was
found that 1 month of therapy on regorafenib is associated
with lower spending than any of the alternatives, with full
course of regorafenib amounting to 292 thousand rubles
per patient, which is 481 thousand roubles (62%) lower
than full course of cetuximab and 676 thousand roubles
(70%) lower than treatment with panitumumab. Budget
impact analysis demonstrated that inclusion of regorafenib
in ONLP system would allow to reduce budget spending by
261,98 million rubles during first year, 255 million roubles
on second year and 248 million roubles on the third year.
Sensitivity analysis confirms the stability of the results.
These results indicate that expansion of regorafenib’s
use in colorectal patients in the Russian federation
would be associated with reduction in spending, and its
inclusion in ONLP woulr result in reduction of budget
burden associated with government guarantees of free
medical help. It should also be noted that unlike all other
alternatives regorafenib would also be able to adequately
address the needs of patients with mutant KRAS that
currently have limited therapeutic options in ONLP context.
e:
aecheberda@healtheconomics.ru